Market Overview

The Global Antisense & RNAi Therapeutics Market was valued at USD 4,477.6 million in 2023 and is expected to reach USD 16,945.3 million by 2031 while growing at a CAGR of 18.1% during the forecast period (2024-2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global antisense & RNAi therapeutics market growth. Antisense and RNAi therapeutics, a novel class of drugs, act by silencing specific disease-causing RNA through short interfering RNAs (siRNAs) or microRNAs (miRNAs). This approach involves degrading targeted mRNA by RNase, thereby reducing the translation of harmful proteins. These therapeutics target specific genes or gene sequences associated with various diseases, such as neurological disorders, heart disease, cancers, viral infections, etc., suppressing their activity to prevent harm to the body.

The rising prevalence of genetic disorders and rare diseases, along with continuous advancements in RNAi technology including improved delivery methods and enhanced stability of RNA molecules is anticipated to drive significant growth in the antisense & RNAi therapeutics market. Despite this potential, obstacles like the risk of off-target effects and immunogenicity concerns may impede market expansion.

Furthermore, the global antisense & RNAi therapeutics industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Therapeutics Analysis

The Global Antisense & RNAi Therapeutics Market is segmented among RNA Interference, and RNA Antisense, based on Therapeutics. In 2023, RNA Antisense accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Route of Administration Analysis

The Global Antisense & RNAi Therapeutics Market is segmented among Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others, based on Route of Administration. In 2023, Intrathecal Route accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Antisense & RNAi Therapeutics Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Alnylam Pharmaceuticals, Inc., Biogen Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Sarepta Therapeutics, Inc., Silence Therapeutics, Arbutus Biopharma (Formerly Called Tekmira Pharmaceuticals), Isarna Therapeutics GmbH, Gene Signal International SA, Arrowhead Pharmaceuticals, Inc., and Benitec Biopharma Ltd.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Antisense & RNAi Therapeutics Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Antisense & RNAi Therapeutics Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Antisense & RNAi Therapeutics Market Segmentation, By Therapeutics

• Global Antisense & RNAi Therapeutics Market Share Analysis, By Therapeutics

• Global Antisense & RNAi Therapeutics Market Growth Analysis, By Therapeutics

• Global Antisense & RNAi Therapeutics Market Trends, By Therapeutics

o RNA Interference

o RNA Antisense

6. Global Antisense & RNAi Therapeutics Market Segmentation, By Route of Administration

• Global Antisense & RNAi Therapeutics Market Share Analysis, By Route of Administration

• Global Antisense & RNAi Therapeutics Market Growth Analysis, By Route of Administration

• Global Antisense & RNAi Therapeutics Market Trends, By Route of Administration

o Intravenous Route

o Subcutaneous Route

o Intrathecal Route

o Pulmonary Delivery

o Intraperitoneal Injection

o Others

7. Global Antisense & RNAi Therapeutics Market Segmentation, By Indication

• Global Antisense & RNAi Therapeutics Market Share Analysis, By Indication

• Global Antisense & RNAi Therapeutics Market Growth Analysis, By Indication

• Global Antisense & RNAi Therapeutics Market Trends, By Indication

o Autosomal Recessive Disease

o Autosomal Dominant Disease

o Chromosomal Disease

o Others

8. Global Antisense & RNAi Therapeutics Market Segmentation, By Region

• Global Antisense & RNAi Therapeutics Market Share Analysis, By Region

• Global Antisense & RNAi Therapeutics Market Growth Analysis, By Region

• Global Antisense & RNAi Therapeutics Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

9. Competitive Landscape

• Alnylam Pharmaceuticals, Inc. *

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Biogen Inc.

• Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)

• Sarepta Therapeutics, Inc.

• Silence Therapeutics

• Arbutus Biopharma (Formerly Called Tekmira Pharmaceuticals)

• Isarna Therapeutics GmbH

• Gene Signal International SA

• Arrowhead Pharmaceuticals, Inc.

• Benitec Biopharma Ltd 

*Similar analysis will be provided for each company listed above.